
DRI-C21045
CAS No. 2101765-81-3
DRI-C21045( —— )
Catalog No. M26176 CAS No. 2101765-81-3
Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | In Stock |
![]() ![]() |
5MG | 65 | In Stock |
![]() ![]() |
10MG | 110 | In Stock |
![]() ![]() |
25MG | 209 | In Stock |
![]() ![]() |
50MG | 372 | In Stock |
![]() ![]() |
100MG | 556 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameDRI-C21045
-
NoteResearch use only, not for human use.
-
Brief DescriptionDri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.
-
DescriptionDri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM, respectively. Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-protein interaction (PPI) with IC50 of 0.17 μM.
-
In VitroDRI-C21045 (3.2-100 μM; 18 h) concentration-dependently inhibits the CD40L-induced NF-κB activation in CD40 sensor cells.DRI-C21045 (0.6-50 μM; 48 h) blocks CD40L-induced functional activation of primary B cells.DRI-C21045 (0.4-50 μM; 48 h) inhibits CD40L-induced MHC-II upregulation in THP-1 cells.DRI-C21045 (2-100 μM; 48 h) inhibits CD40L-induced B cell proliferation.DRI-C21045 shows no signs of cytotoxicity for concentrations of up to 100 and 200 μM and has no genotoxic potential for concentrations of up to 500 μM.
-
In VivoDRI-C21045 (30 mg/kg; daily, s.c.; in 20% HPβCD) prolongs graft survival in a murine allogeneic skin transplant model.DRI-C21045 (20-60 mg/kg; twice daily s.c.; in 20% HPβCD) inhibits alloantigen-induced T cell expansion in the draining lymph nodes (DLNs). Animal Model:Full-thickness ear skins from BALB/c were transplanted onto the dorsal thorax of C57BL/6 Dosage:30 mg/kg Administration:Daily s.c; administered in 20% w/v hydroxypropyl-β-cyclodextrin (HPβCD) solutionResult:Caused prolongation of skin allograft survival.
-
Synonyms——
-
PathwayApoptosis
-
TargetNF-κB
-
Recptoranandamide cellular uptake
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2101765-81-3
-
Formula Weight580.61
-
Molecular FormulaC32H24N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (3.44 mM)
-
SMILESCOC(=O)c1ccc(cc1)C(=O)Nc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1cccc2cccc(c12)S(O)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ortar G, et al. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol. 2003 May 1;65(9):1473-81.
molnova catalog



related products
-
SR12343
SR12343 (SR-12343) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation.
-
SP-100030
SP-100030 is a dual inhibitor of NF-κB and activator protein-1 (AP-1), demonstrating potent inhibition with IC50 values of 50 nM for both.
-
Atractylodin
Atractylodin has high lipase inhibitory activity (IC5:39.12?μM); Atractylodin possesses strong repellency activities against T. castaneum adults (LD50: 1.83?μg/cm).